Ahead of the WHO’s World Hepatitis Day, EAHP’s EU Monitor highlights a recent EJHP article by Mark Nolan on the use of antiviral protease inhibitors Telaprevir and Boceprevir for the treatment of Hepatitis C.
The article discus

ses some of the special points about both medicines, including patient counselling around such issues as adverse reactions, drug interactions and medication storage.

Full article available here